Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition),Liver Cancer

当前位置： X-MOL 学术 › Liver Cancer › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)
Liver Cancer ( IF 11.6 ) Pub Date : 2023-04-05 , DOI: 10.1159/000530495
Jian Zhou ₁ , Huichuan Sun ₁ , Zheng Wang ₁ , Wenming Cong ₂ , Mengsu Zeng ₃ , Weiping Zhou ₄ , Ping Bie ₅ , Lianxin Liu ₆ , Tianfu Wen ₇ , Ming Kuang ₈ , Guohong Han ₉ , Zhiping Yan ₁₀ , Maoqiang Wang ₁₁ , Ruibao Liu ₁₂ , Ligong Lu ₁₃ , Zhenggang Ren ₁ , Zhaochong Zeng ₁₄ , Ping Liang ₁₅ , Changhong Liang ₁₆ , Min Chen ₁₇ , Fuhua Yan ₁₈ , Wenping Wang ₁₉ , Jinlin Hou ₂₀ , Yuan Ji ₂₁ , Jingping Yun ₂₂ , Xueli Bai ₂₃ , Dingfang Cai ₂₄ , Weixia Chen ₂₅ , Yongjun Chen ₂₆ , Wenwu Cheng ₂₇ , Shuqun Cheng ₄ , Chaoliu Dai ₂₈ , Wengzhi Guo ₂₉ , Yabing Guo ₃₀ , Baojin Hua ₃₁ , Xiaowu Huang ₁ , Weidong Jia ₃₂ , Qiu Li ₃₃ , Tao Li ₃₄ , Xun Li ₃₅ , Yaming Li ₃₆ , Yexiong Li ₃₇ , Jun Liang ₃₈ , Changquan Ling ₃₉ , Tianshu Liu ₄₀ , Xiufeng Liu ₄₁ , Shichun Lu ₄₂ , Guoyue Lv ₄₃ , Yilei Mao ₄₄ , Zhiqiang Meng ₄₅ , Tao Peng ₄₆ , Weixin Ren ₄₇ , Hongcheng Shi ₄₈ , Guoming Shi ₁ , Ming Shi ₈ , Tianqiang Song ₄₉ , Kaishan Tao ₅₀ , Jianhua Wang ₁₀ , Kui Wang ₄ , Lu Wang ₅₁ , Wentao Wang ₇ , Xiaoying Wang ₁ , Zhiming Wang ₅₂ , Bangde Xiang ₅₃ , Baocai Xing ₅₄ , Jianming Xu ₅₅ , Jiamei Yang ₄ , Jianyong Yang ₅₆ , Yefa Yang ₅₇ , Yunke Yang ₂₄ , Shenglong Ye ₁ , Zhenyu Yin ₅₈ , Yong Zeng ₇ , Bixiang Zhang ₅₉ , Boheng Zhang ₁ , Leida Zhang ₆₀ , Shuijun Zhang ₆₁ , Ti Zhang ₅₁ , Yanqiao Zhang ₆₂ , Ming Zhao ₆₃ , Yongfu Zhao ₆₁ , Honggang Zheng ₆₄ , Ledu Zhou ₆₅ , Jiye Zhu ₆₆ , Kangshun Zhu ₆₇ , Rong Liu ₁₀ , Yinghong Shi ₁ , Yongsheng Xiao ₁ , Lan Zhang ₁ , Chun Yang ₃ , Zhifeng Wu ₁₄ , Zhi Dai ₁ , Minshan Chen ₈ , Jianqiang Cai ₆₈ , Weilin Wang ₆₉ , Xiujun Cai ₂₃ , Qiang Li ₄₉ , Feng Shen ₄ , Shukui Qin ₄₁ , Gaojun Teng ₇₀ , Jiahong Dong ₇₁ , Jia Fan ₁

Affiliation

Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Pathology, The Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Department of Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
The Third Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Institute of Hepatobiliary Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.
Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
Department of Liver Surgery, West China Hospital of Sichuan University, Chengdu, China.
Department of Hepatobiliary Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Department of Liver Diseases and Digestive Interventional Radiology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Interventional Radiology, Chinese PLA General Hospital, Beijing, China.
Department of Interventional Radiology, The Tumor Hospital of Harbin Medical University, Harbin, China.
Department of Interventional Oncology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Department of Radiation Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Interventional Ultrasound, Chinese PLA General Hospital, Beijing, China.
Department of Radiology, Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China.
Editorial Department of Chinese Journal of Digestive Surgery, Chongqing, China.
Department of Radiology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, China.
Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Pathology, Tumor Prevention and Treatment Center, Sun Yat-sen University, Guangzhou, China.
Department of Hepatobiliary and Pancreatic Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Department of Integrative Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Radiology, West China Hospital of Sichuan University, Chengdu, China.
Department of Hematology, Ruijin Hospital North, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Hepatobiliary and Spleenary Surgery, The Affiliated Shengjing Hospital, China Medical University, Shenyang, China.
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Graduate School, Beijing University of Chinese Medicine, Beijing, China.
Department of Hepatic Surgery, Affiliated Provincial Hospital, Anhui Medical University, Hefei, China.
Department of Oncology, West China Hospital, Sichuan University, Chengdu, China.
Department of General Surgery, Qilu Hospital, Shandong University, Jinan, China.
The First Hospital of Lanzhou University, Lanzhou, China.
Department of Nuclear Medicine, The First Hospital of China Medical University, Shenyang, China.
Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Oncology, Peking University International Hospital, Beijing, China.
Changhai Hospital of Traditional Chinese Medicine, Second Military Medical University, Shanghai, China.
Department of Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Medical Oncology, PLA Cancer Center, Nanjing Bayi Hospital, Nanjing, China.
Institute and Hospital of Hepatobiliary Surgery of Chinese PLA, Chinese PLA Medical School, Chinese PLA General Hospital, Beijing, China.
Department of General Surgery, The First Hospital of Jilin University, Jilin, China.
Department of Liver Surgery, Peking Union Medical College (PUMC) Hospital, PUMC and Chinese Academy of Medical Sciences, Beijing, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Department of Interventional Radiology the First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai, China.
Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.
Department of Infectious Diseases, Xiangya Hospital, Central South University, Changsha, China.
Department of Hepatobiliary Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
Department of Hepato-Pancreato-Biliary Surgery, Peking University Cancer Hospital and Institute, Beijing, China.
Department of Gastrointestinal Oncology, Affiliated Hospital Cancer Center, Academy of Military Medical Sciences, Beijing, China.
Department of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Department of Hepatic Surgery and Interventional Radiology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Department of Hepatobiliary Surgery, Zhongshan Hospital of Xiamen University, Xiamen, China.
Department of Surgery, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Hepatobiliary Surgery Institute, Southwest Hospital, Third Military Medical University, Chongqing, China.
Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital of Zhengzhou University, ZhengZhou, China.
Department of Gastrointestinal Medical Oncology, The Affiliated Tumor Hospital of Harbin Medical University, Harbin, China.
Minimally Invasive Interventional Division, Liver Cancer Group, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Department of Oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Department of General Surgery, Xiangya Hospital, Central South University, Changsha, China.
Department of Hepatobiliary Surgery, Peking University People's Hospital, Beijing, China.
Department of Minimally Invasive Interventional Radiology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
Department of Abdominal Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Department of Hepatobiliary and Pancreas Surgery, Beijing Tsinghua Changgung Hospital (BTCH), School of Clinical Medicine, Tsinghua University, Beijing, China.

Background: Primary liver cancer, around 75%–85% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China in June 2017, which were updated by the National Health Commission in December 2019, additional high-quality evidence has emerged from researchers worldwide regarding the diagnosis, staging, and treatment of liver cancer, that requires the guidelines to be updated again. The new edition (2022 Edition) was written by more than 100 experts in the field of liver cancer in China, which not only reflects the real-world situation in China, but also may re-shape the nationwide diagnosis and treatment of liver cancer. Key Messages: The new guideline aims to encourage the implementation of evidence-based practice, and improve the national average five-year survival rate for patients with liver cancer, as proposed in the "Health China 2030 Blueprint."

更新日期：2023-04-05

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文